June 2021

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

ByMary Caffrey

June 22nd 2021

Observations Regarding the Average Sales Price Reimbursement Methodology

BySusan Weidner, MBA, MS,Michael Diaz, MD,Cass Schaedig,Lucio Gordan, MD

June 21st 2021

Weidner et al, Appendices

BySusan Weidner, MBA, MS,Michael Diaz, MD,Cass Schaedig,Lucio Gordan, MD

June 21st 2021

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

Real-World Evidence Is Key to Accelerating Oncology Approvals

ByJennifer B. Christian, PharmD, MPH, PhD

June 21st 2021

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

ByAllison Inserro

June 20th 2021

Biosimilars Drive Savings in Medicare’s Oncology Care Model

ByKeely Macmillan, MSPH

June 19th 2021

A Social Worker Leads ACCC, and Her Timing Is Perfect

ByMary Caffrey

June 19th 2021

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

ByMary Caffrey

May 26th 2021

Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.

June 2021

Dollars and Sense

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

Observations Regarding the Average Sales Price Reimbursement Methodology

Weidner et al, Appendices

Real-World Evidence Is Key to Accelerating Oncology Approvals

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

Biosimilars Drive Savings in Medicare’s Oncology Care Model

A Social Worker Leads ACCC, and Her Timing Is Perfect

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

5 Things to Know About the Oral GLP-1 Era

Exploring Identity, Appearance Experiences Among Patients With Alopecia

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Real-World Evidence Backs Acalabrutinib in CLL Care